Development, Validation, and Application of an LC–MS/MS Method for Pharmacokinetic Studies for the Datopotamab Deruxtecan‐Dlnk Quantification in Rat Plasma
Biomedical Chromatography · 2026-08 · 40 (8)
DOI: 10.1002/bmc.70542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 08.07.2026. Verfasst von Lurdhu Mary K und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology and Research,…. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Immunoconjugates. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
To quantify datopotamab deruxtecan‐dlnk in rat plasma, a selective, sensitive, and quick LC–MS/MS technique was created, validated, and successfully used in pharmacokinetic investigations. The analyte separation was accomplished on an Agilent Eclipse XDB‐C18 analytical column (150 × 4.6 mm, 3.5 μm particle size) employing isocratic elution using an acetonitrile and buffer mobile phase (50:50, v/v) delivered at 1.0 mL/min. The internal standard was tisotumab vedotin. Mass spectrometric analysis was conducted using electrospray ionization (ESI) operated in the multiple reaction monitoring (MRM) mode. A simple and efficient protein precipitation technique was employed to prepare the sample. The method demonstrated remarkable linearity within the range of 25–1000 ng/mL, with an r 2 value exceeding 0.999. Accuracy values ranged between 93.76% and 106.23%, with corresponding intraday and interday precision values being within reasonable bounds. There were no discernible matrix effects, and recovery was reliable and repeatable. Datopotamab deruxtecan‐dlnk was found to be stable under all tested conditions, according to stability studies. After intravenous injection, the validated approach was effectively applied to pharmacokinetic research in rats, allowing for accurate estimates of important pharmacokinetic parameters. This approach is ideal for routine bioanalysis and pharmacokinetic evaluation of datopotamab deruxtecan‐dlnk in preclinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology and Research, Guntur, Andhra Pradesh, India.
- Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology and Research, Yadadri Bhuvangiri, Telangana, India.
ORCID-Profile: Lurdhu Mary K
Zitieren
APA
Mary K, L., Podila, N., & Maddula, V. R. (2026). Development, Validation, and Application of an LC–MS/MS Method for Pharmacokinetic Studies for the Datopotamab Deruxtecan‐Dlnk Quantification in Rat Plasma. Biomedical Chromatography, 40(8). https://doi.org/10.1002/bmc.70542
Vancouver
Mary K L, Podila N, Maddula VR. Development, Validation, and Application of an LC–MS/MS Method for Pharmacokinetic Studies for the Datopotamab Deruxtecan‐Dlnk Quantification in Rat Plasma. Biomedical Chromatography. 2026;40(8). doi:10.1002/bmc.70542
BibTeX
@article{MaryK2026,
author = {Mary K, Lurdhu and Podila, Naresh and Maddula, Venkata Ramana},
title = {Development, Validation, and Application of an LC–MS/MS Method for Pharmacokinetic Studies for the Datopotamab Deruxtecan‐Dlnk Quantification in Rat Plasma},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {8},
doi = {10.1002/bmc.70542}
}
EUVIMED